{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:16:15Z","timestamp":1788243375217,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.eplepsyres.2010.01.014","type":"journal-article","created":{"date-parts":[[2010,3,18]],"date-time":"2010-03-18T04:33:34Z","timestamp":1268886814000},"page":"278-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":168,"title":["Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy"],"prefix":"10.1016","volume":"89","author":[{"given":"E.","family":"Ben-Menachem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Gabbai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hufnagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Soares-da-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2010.01.014_bib1","series-title":"The Treatment of Epilepsy","first-page":"485","article-title":"Eslicarbazepine acetate","author":"Almeida","year":"2009"},{"key":"10.1016\/j.eplepsyres.2010.01.014_bib2","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1177\/0091270005279364","article-title":"Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects","volume":"45","author":"Almeida","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2010.01.014_bib3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00228-007-0414-1","article-title":"Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment","volume":"64","author":"Almeida","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2010.01.014_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1023\/A:1014814924965","article-title":"Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024","volume":"27","author":"Ambrosio","year":"2002","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.eplepsyres.2010.01.014_bib5","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1021\/jm980627g","article-title":"Anticonvulsant and sodium channel-blocking properties of novel 10,11- dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives","volume":"42","author":"Benes","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.eplepsyres.2010.01.014_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.09.005","article-title":"Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX)","volume":"83","author":"Bialer","year":"2009","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2010.01.014_bib7","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"Proposal for revised clinical and electroencephalographic classification of epileptic seizures","volume":"22","author":"Commission on Classification and Terminology of the International League Against Epilepsy","year":"1981","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2010.01.014_bib8","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1528-1167.2007.00984.x","article-title":"Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures","volume":"48","author":"Elger","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2010.01.014_bib9","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","article-title":"Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study","volume":"50","author":"Elger","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2010.01.014_bib10","unstructured":"EMEA\/CPMP, Committee for Proprietary Medicinal Products (CPMP). Note for guidance on clinical investigation of medicinal products in the treatment of epileptic disorders. London, 16 November 2000 (CPMP\/EWP\/566\/98 rev 1)."},{"key":"10.1016\/j.eplepsyres.2010.01.014_bib11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/bdd.549","article-title":"Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker","volume":"28","author":"Falcao","year":"2007","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.eplepsyres.2010.01.014_bib12","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/0126839-200809060-00007","article-title":"Dosage form proportionality and food effect of the final tablet formulation of eslicarbazepine acetate: randomized, open-label, crossover, single-centre study in healthy volunteers","volume":"9","author":"Fontes-Ribeiro","year":"2008","journal-title":"Drugs R&D"},{"key":"10.1016\/j.eplepsyres.2010.01.014_bib13","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.WNL.0000123695.22623.32","volume":"62","author":"French","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2010.01.014_bib14","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2010.01.014_bib15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/00126839-200506040-00002","article-title":"Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093)","volume":"6","author":"Maia","year":"2005","journal-title":"Drugs R&D"},{"issue":"Suppl. 4","key":"10.1016\/j.eplepsyres.2010.01.014_bib16","first-page":"196","article-title":"Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with epilepsy","volume":"50","author":"Perucca","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2010.01.014_bib17","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1474-4422(07)70215-6","article-title":"Development of new antiepileptic drugs: challenges, incentives, and recent advances","volume":"6","author":"Perucca","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2010.01.014_bib18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/brain\/awh682","article-title":"Molecular and cellular mechanisms of pharmacoresistance in epilepsy","volume":"129","author":"Remy","year":"2006","journal-title":"Brain"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121110000355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121110000355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:23:23Z","timestamp":1760275403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121110000355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":18,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S0920121110000355"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2010.01.014","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.722859897.793506022","asserted-by":"object"}]},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2010.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}